文献速递妇科

盆腔重建手术疼痛管理综合模型的前瞻性临床实践研究

A comprehensive model for pain management in patients undergoing pelvic reconstructive surgery: a prospective clinical practice study.
PubMed 文献 · Am J Obstet Gynecol · 2020-05-13

本研究前瞻性纳入113例盆腔重建手术患者,采用加速康复外科方案及多模式镇痛,出院时电子处方开具15片口服阿片类药物。结果显示出院后阿片消耗中位仅24.0 MME(不足4片羟考酮5mg),10.6%需补开,患者满意度高。

要点

  • 出院后阿片消耗低,中位24.0 MME,不足4片羟考酮5mg。
  • 75%患者使用少于11片羟考酮5mg,约三分之一未用阿片。
  • 总体补开率10.6%,电子补开流程便捷。

核心结论

  • 盆腔重建术后多数患者阿片用量少,中位出院后消耗24.0 MME,不足4片羟考酮5mg。

研究设计与样本

  • 前瞻性临床实践研究,纳入2018年12月至2019年6月113例住院盆腔重建手术女性,术后留宿。

主要发现

  • 处方阿片中位112.5 MME(IQR 112.5-112.5),出院后消耗中位24.0 MME(IQR 0-82.5)。
  • 未使用阿片中位90.0 MME(IQR 45-112.5),总体补开率10.6%(12/113)。
  • 术后1周和4-6周满意度分别为81.4%(92/113)和83.2%(94/113)。
  • 88.5%(100/113)患者认为出院阿片数量足够,术后4-6周19.5%患者取药但未用。

关键数值与推荐

  • 出院带药为15片口服阿片,通过电子处方平台开具。
  • 术后1周和4-6周进行电话随访,评估疼痛、剩余药片及满意度。

临床怎么用

  • 盆腔重建术后可限制阿片处方数量,依托电子处方系统便捷补开。
  • 疼痛和活动评分与阿片使用不相关,不应仅凭评分增加阿片处方。

局限性

  • 单中心前瞻性研究,样本量113例,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative opioid prescription patterns play a key role in driving the opioid epidemic. A comprehensive system toward pain management in surgical patients is necessary to minimize overall opioid consumption. OBJECTIVE: This study aimed to evaluate the efficacy of a pain management model in patients undergoing pelvic reconstructive surgery by measuring postdischarge narcotic use in morphine milligram equivalents. STUDY DESIGN: This is a prospective clinical practice study that included women undergoing inpatient pelvic reconstructive surgery from December 2018 to June 2019 with overnight stay after surgery. As a routine protocol, all the patients followed an enhanced recovery after surgery protocol that included a preoperative multimodal pain regimen. Brief Pain Inventory surveys were collected preoperatively and on postoperative day 1. Brief pain inventory and activities assessment scale scores were collected at postoperative week 1 and postoperative weeks 4-6 after surgery. Patients were discharged with 15 tablets of an oral narcotic using an electronic prescription for controlled substances software platform, which is mandated in the state of Connecticut for all controlled substances, prescriptions, and refills. Patients were called at postoperative week 1 and postoperative weeks 4-6 to answer questions regarding their pain, the number of remaining narcotic tablets, and patient satisfaction regarding pain management. Patient electronic medical records and the Connecticut Prescription Monitoring and Reporting System were reviewed to determine whether patients received narcotic refills. Primary outcome was postdischarge narcotic use measured in morphine milligram equivalents. Secondary outcomes evaluated refill rate, brief pain inventory and activities assessment scale scores, and patient satisfaction with pain management. Descriptive statistics were described as mean and standard deviation and median and interquartile range. Bivariate comparisons used Spearman's rho (ρ) with α=0.05. RESULTS: A total 113 patients were enrolled; the median (interquartile range) morphine milligram equivalent prescribed (including refills) was 112.5 (112.5-112.5). The median postdischarge narcotic use was 24.0 (0-82.5) morphine milligram equivalent, which is equivalent to fewer than 4 oxycodone (5 mg) tablets. About 75% of our participants required fewer than 11 oxycodone tablets. The median unused morphine milligram equivalent was 90.0 (45-112.5). 81.4% (92/113), and 83.2% (94/113) of patients at postoperative week 1 and postoperative weeks 4-6, respectively, reported being satisfied or extremely satisfied with their postdischarge pain control. About 88.5% (100/113) of patients felt that the number of opioids they were discharged with was sufficient for their pain needs at the postoperative 1 and postoperative weeks 4-6 time points. At postoperative weeks 4-6, 19.5% of patients said that they filled the narcotic prescription but did not use any of the pills. The overall refill rate was 10.6% (12/113). All patients who needed a refill described the refill process as easy. In-hospital narcotic use was not predictive of postdischarge narcotic use (ρ0.065, P=.495). Patients reported median brief pain inventory scores for "average pain" of 0 (no pain) at postoperative week 1 and postoperative weeks 4-6; however, the scores did not clinically correlate with postdischarge narcotic use. Activities assessment scale scores were not correlated with postdischarge narcotic use. CONCLUSION: Most patients after pelvic reconstructive surgery used fewer than 11 oxycodone (5 mg) tablets, averaging less than 4 tablets, with a third of patients not requiring any opioids. Pain and activities scores did not correlate with narcotic use. A minimal number of opioids can be prescribed because the secure electronic prescribing system allows for convenient electronic refill if required. Our practical and comprehensive pre- and postoperative protocol for pain management minimizes opioid consumption in addition to maximizing patient satisfaction.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Ramaseshan AS, O'Sullivan DM, Steinberg AC, et al. A comprehensive model for pain management in patients undergoing pelvic reconstructive surgery: a prospective clinical practice study. Am J Obstet Gynecol. 2020. PMID: 32413429. doi:10.1016/j.ajog.2020.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。